Shares of Eli Lilly And Co (NYSE:LLY) have received an average recommendation of “Buy” from the sixteen analysts that are covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $130.11.
Several equities analysts recently weighed in on the stock. UBS Group reduced their target price on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating on the stock in a report on Thursday, October 17th. TheStreet upgraded shares of Eli Lilly And Co from a “c+” rating to a “b-” rating in a report on Friday, November 8th. Finally, Bank of America assumed coverage on shares of Eli Lilly And Co in a report on Wednesday, October 16th. They set a “buy” rating and a $133.00 target price on the stock.
Shares of LLY traded up $1.03 during mid-day trading on Thursday, reaching $115.10. The company had a trading volume of 3,533,338 shares, compared to its average volume of 7,541,104. The stock has a market cap of $108.68 billion, a price-to-earnings ratio of 20.74, a price-to-earnings-growth ratio of 1.85 and a beta of 0.16. The firm has a fifty day simple moving average of $110.55 and a 200-day simple moving average of $112.44. Eli Lilly And Co has a fifty-two week low of $101.36 and a fifty-two week high of $132.13. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 4.09.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a dividend of $0.645 per share. The ex-dividend date of this dividend is Thursday, November 14th. This represents a $2.58 annualized dividend and a dividend yield of 2.24%. Eli Lilly And Co’s payout ratio is 46.49%.
In other Eli Lilly And Co news, CFO Joshua L. Smiley bought 929 shares of Eli Lilly And Co stock in a transaction that occurred on Friday, October 25th. The shares were acquired at an average price of $107.59 per share, for a total transaction of $99,951.11. Following the acquisition, the chief financial officer now owns 31,524 shares of the company’s stock, valued at approximately $3,391,667.16. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, SVP Alfonso G. Zulueta sold 4,500 shares of Eli Lilly And Co stock in a transaction on Friday, September 20th. The shares were sold at an average price of $117.00, for a total transaction of $526,500.00. Following the transaction, the senior vice president now owns 33,806 shares in the company, valued at approximately $3,955,302. The disclosure for this sale can be found here. In the last 90 days, insiders have purchased 8,405 shares of company stock worth $909,004 and have sold 625,071 shares worth $71,766,474. Insiders own 0.11% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in LLY. Capital Investment Advisory Services LLC grew its position in shares of Eli Lilly And Co by 3.4% during the 2nd quarter. Capital Investment Advisory Services LLC now owns 2,831 shares of the company’s stock valued at $304,000 after buying an additional 92 shares during the last quarter. Investors Research Corp boosted its stake in Eli Lilly And Co by 5.6% during the 3rd quarter. Investors Research Corp now owns 1,764 shares of the company’s stock valued at $197,000 after purchasing an additional 93 shares during the period. Global Wealth Management Investment Advisory Inc. boosted its stake in Eli Lilly And Co by 10.2% during the 2nd quarter. Global Wealth Management Investment Advisory Inc. now owns 1,023 shares of the company’s stock valued at $113,000 after purchasing an additional 95 shares during the period. FTB Advisors Inc. boosted its stake in Eli Lilly And Co by 3.0% during the 3rd quarter. FTB Advisors Inc. now owns 3,275 shares of the company’s stock valued at $366,000 after purchasing an additional 95 shares during the period. Finally, Lourd Capital LLC boosted its stake in Eli Lilly And Co by 2.7% during the 2nd quarter. Lourd Capital LLC now owns 3,723 shares of the company’s stock valued at $412,000 after purchasing an additional 97 shares during the period. 76.52% of the stock is currently owned by hedge funds and other institutional investors.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: Outstanding Shares
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.